Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis
Yoshiyuki Morishita 1, *, Eiji Kusano 2, Daisuke Nagata 1
Identifiers and Pagination:Year: 2014
First Page: 6
Last Page: 11
Publisher ID: TOCMJ-8-6
Article History:Received Date: 1/1/2013
Revision Received Date: 1/1/2014
Acceptance Date: 5/1/2014
Electronic publication date: 7 /2/2014
Collection year: 2013
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
The renin-angiotensin-aldosterone system (RAAS) blockers have been widely used in chronic kidney disease patients undergoing hemodialysis; however, whether RAAS blockers have beneficial effects for cardiovascular disease in those patients has not been fully defined. This review focuses on the effects of RAAS blockers in chronic kidney disease undergoing hemodialysis for cardiovascular disease.